abstract |
(57) [Summary]nProvided are inhibitors of HIV protease. When binding to HIV protease, the inhibitor is characterized by having a unique orientation to the S1, S1 ', S2, S2', S3 and S3 'subsites of the unique three-dimensional conformational protease. Also provided are pharmaceutical compositions containing the inhibitors and methods of treating HIV infection. |